[Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].

Alicia Méndez-Gómez, Noemí Gómez-Hernández, Margarita Ortega-Cisneros, Bricia Melissa Gutiérrez-Zepeda, Antonio de Jesús Quintero-Rodríguez, Luis Alberto Duran-Marín, Marya Lizzeth Rosaldo-Solís, Antonio Quintero-Ramos
{"title":"[Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].","authors":"Alicia Méndez-Gómez, Noemí Gómez-Hernández, Margarita Ortega-Cisneros, Bricia Melissa Gutiérrez-Zepeda, Antonio de Jesús Quintero-Rodríguez, Luis Alberto Duran-Marín, Marya Lizzeth Rosaldo-Solís, Antonio Quintero-Ramos","doi":"10.5281/zenodo.19099403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment.</p><p><strong>Objective: </strong>To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT).</p><p><strong>Material and methods: </strong>A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed.</p><p><strong>Results: </strong>The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%.</p><p><strong>Conclusions: </strong>The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"64 Suppl 1","pages":"e6671"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268660/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.19099403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment.

Objective: To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT).

Material and methods: A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed.

Results: The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%.

Conclusions: The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases.

【继发性免疫缺陷患者免疫球蛋白替代治疗的临床概况】。
背景:继发性免疫缺陷(SID)是一种免疫系统受到外部或后天因素损害,导致免疫球蛋白数量或功能降低的疾病。这种情况增加了对专家咨询、随访和替代治疗的需求,这反过来又增加了医疗保健费用。迄今为止,很少有研究具有SID患者的临床特征;因此,了解它们的特征将有助于改进管理和治疗。目的:描述SID患者接受人免疫球蛋白替代治疗(IgG-RT)的临床概况。材料和方法:回顾40例SID患者接受IgG-RT治疗的病历,进行回顾性观察性研究。分析了替代治疗的危险因素和益处。结果:平均年龄48岁,以女性居多(62.5%)。最常见的疾病是风湿病(38%),其次是血液病(31%)和蛋白质流失疾病(27%)。所有患者均接受了皮质类固醇联合另一种免疫抑制剂,77.5%的患者也接受了利妥昔单抗治疗。50%的病例有感染记录;然而,只有35%的人接受了预防。22.5%的患者复发,死亡率为2.5%。结论:皮质类固醇和免疫抑制剂的使用,特别是利妥昔单抗,是SID的主要原因,主要与风湿病和血液病相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书